State-of-the art pharmacotherapy for non-neovascular age-related macular degeneration.

State-of-the art pharmacotherapy for non-neovascular age-related macular degeneration. Expert Opin Pharmacother. 2020 Mar 10;: Authors: Veritti D, Sarao V, Samassa F, Danese C, Löwenstein A, Schmidt-Erfurth U, Lanzetta P Abstract IntroductionAge-related macular degeneration (AMD) is the most common cause of blindness among the elderly in the industrialized world. While effective treatment is available for neovascular AMD, no therapy is successful for the non-neovascular form. Herein, the authors report the current knowledge on non-neovascular AMD pathogenesis and the promising research on treatments.Areas coveredIn the present review, the authors summarize the most recent advances in the treatment of non-neovascular AMD and provide an update on current treatment strategies. Evidence available from preclinical and clinical studies and from a selective literature search is reported.Expert opinionWhen investigating AMD, numerous pathological cascades and alterations of physiological processes have been investigated. It is well-known that AMD is a multifactorial disease, with environmental causes and genetics playing a role. Perturbations in multiple pathogenic pathways have been identified and this led to the development of several molecules directed at specific therapeutic targets.However, despite the huge research effort, the only proven approach so far is oral antioxidant supplementation. We believe that, in addition to successful a...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research